Molecular and Cellular Biology, October 1999, p. 6742-6753, Vol. 19, No. 10
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Institute of Molecular Pharmacology, Medical School Hannover, D-30625 Hannover, Germany1; Fred Hutchinson Cancer Research Center, Seattle, Washington 981092; and Department of Membrane Research and Biophysics, The Weizmann Institute of Sciences, 76100 Rehovot, Israel3
Received 10 February 1999/Returned for modification 5 March 1999/Accepted 23 June 1999
| |
ABSTRACT |
|---|
|
|
|---|
A hallmark of inflammation is the burst-like formation of certain
proteins, initiated by cellular stress and proinflammatory cytokines
like interleukin 1 (IL-1) and tumor necrosis factor, stimuli which
simultaneously activate different mitogen-activated protein (MAP)
kinases and NF-
B. Cooperation of these signaling pathways to induce
formation of IL-8, a prototype chemokine which causes leukocyte
migration and activation, was investigated by expressing active and
inactive forms of protein kinases. Constitutively active MAP kinase
kinase 7 (MKK7), an activator of the stress-activated protein
kinase/c-Jun N-terminal kinase (SAPK/JNK) pathway, induced IL-8
synthesis and transcription from a minimal IL-8 promoter. Furthermore,
MKK7 synergized in both effects with NF-
B-inducing kinase (NIK).
Activation of the IL-8 promoter by either of the kinases required
functional NF-
B and AP-1 sites. While NIK and MKK7 did not affect
degradation of IL-8 mRNA, an active form of MKK6, which selectively
activates p38 MAP kinase, induced marked stabilization of the
transcript and further increased IL-8 protein formation induced by NIK
plus MKK7. Consistently, the MAP kinase kinase kinase MEKK1, which can
activate NF-
B, SAPK/JNK, and p38 MAP kinases, most potently induced
IL-8 formation. These results provide evidence that maximal IL-8 gene
expression requires the coordinate action of at least three different
signal transduction pathways which cooperate to induce mRNA synthesis
and suppress mRNA degradation.
| |
INTRODUCTION |
|---|
|
|
|---|
Interleukin-8 (IL-8) is a member of
the still-growing family of chemokines, cytokines whose main function
is to attract and activate leukocytes (2). It plays a
significant role in recruiting leukocytes at sites of acute
inflammation. On the other hand, excessive amounts of locally produced
IL-8 can have deleterious effects (2, 45). Expectedly,
therefore, IL-8 gene expression is tightly controlled at several levels
(45). IL-8 synthesis, low or undetectable in normal
noninflamed tissue, can be induced in vivo as well as in a wide variety
of cells in vitro by proinflammatory cytokines such as IL-1 or tumor
necrosis factor (TNF) (21, 5) or as a direct consequence of
contact with pathogens like bacteria (1, 18), viruses
(35, 46), and cell-stressing agents (10, 30, 54,
57). Stimulus-dependent activation of IL-8 gene transcription has
been demonstrated in nuclear run-on experiments (5, 21). In
a number of studies, it was found that a sequence spanning nucleotides
1 to
133 within the 5' flanking region of the IL-8 gene is
essential and sufficient for transcriptional regulation of the gene
(16, 43; reviewed in reference 45). As demonstrated by
mutational and deletional analysis, this promoter element is regulated
in a highly cell-type-specific fashion. The promoter contains an
NF-
B element that is required for activation in all cell types
studied, as well as AP-1 and C/EBP binding sites. The latter two sites
are dispensable for transcriptional activation in some cells but
contribute to activation in others. Thus, unlike the NF-
B site, the
AP-1 and C/EBP sites are not essential for induction (1, 5, 16,
18, 21, 25, 30, 35, 36, 44-46, 64).
Formation of cytokines may also be restricted by mechanisms regulating mRNA half-life. Rapid degradation of cytokine transcripts has been ascribed to AU-rich sequences in their 3' untranslated regions (UTRs) and distinct proteins interacting with them (7, 55). AU-rich sequences are also present in the 3' UTR of IL-8 mRNA. Several reports indicate that IL-8 mRNA degradation is subject to modulation (6, 23, 58, 59, 61), and it has been suggested that the proinflammatory cytokines IL-1 and TNF also control IL-8 formation on this level (6, 21, 58, 59, 61).
Stimuli that induce IL-8 production, like IL-1 and TNF, simultaneously
activate stress protein kinase cascades that regulate the activity of
transcription factors which can bind to NF-
B, AP-1, and C/EBP
binding sites. NF-
B is a dimeric transcription factor retained in
the cytoplasm by its binding to I
B proteins. Recently two I
B
kinases (I
BK
and -
) which specifically phosphorylate two
adjacent serines in I
B proteins have been identified (12, 37,
51, 53, 63, 67). This phosphorylation results in ubiquitination
and rapid degradation of I
Bs by the proteasome, allowing NF-
B to
translocate to the nucleus and bind to DNA. This process is critical
for NF-
B activation, but enhanced NF-
B-induced transcriptional
activity might additionally require phosphorylation of the subunits as
well as binding of coactivators (3, 4, 60). I
B kinases
and
are phosphorylated by NF-
B-inducing kinase (NIK), a
recently identified protein activated by IL-1, TNF, and Fas
(33). I
B kinases can also be directly activated by MEKK1
(28, 29, 47), a mitogen-activated protein (MAP) kinase
kinase kinase which activates the three best-characterized MAP kinases,
namely, extracellular regulated kinase (ERK) (26), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) (31, 66), and p38 MAP kinase (15, 22, 31). The
transcriptional regulator AP-1 is a dimer composed of Fos, Jun, ATF-2,
and other family members (reviewed in references 20
and 62). In contrast to NF-
B, AP-1 proteins are
usually constitutively bound to their cognate DNA elements.
Transcriptional activity of AP-1 proteins is regulated by their
abundance, by phosphorylation of transactivation domains, and by their
binding to protein kinases (20, 62). Protein kinases
activating AP-1 include the ERKs, SAPK/JNK, p38 MAP kinases (20,
62), and a partially characterized Fos kinase (11).
Despite the rapid progress in identifying stress-induced signaling pathways and, on the other hand, structural elements important in transcriptional activation, there is little information on how different signaling pathways interact with each other in order to mediate a particular biological response, such as expression of a gene like that encoding IL-8. In that context, it is of importance to determine not only how stress kinase pathways cooperate to regulate promoter activity but also how they affect steps other than transcription in the overall process of gene expression.
We have recently identified the IL-6 and IL-8 genes as new target genes
regulated by SAPK/JNK (24). This result raised the question
by which molecular mechanism this pathway contributes to IL-8 gene
expression and how this compares to the activation of NF-
B, which
plays a major role in IL-8 transcription.
In this study, we investigated the contribution of NF-
B and
stress-activated protein kinase cascades to IL-8 transcription, mRNA
stability, and protein formation by overexpressing selective upstream
activators for each pathway. We provide evidence for coordinated but
distinct function of each of the pathways in IL-8 gene expression.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Cells and Materials.
KB and HEK-293 cells were obtained from
the American Type Culture Collection. HeLa cells stably transfected
with plasmid pUHD15-1 expressing the tet transactivator
protein (14) were obtained from Hermann Bujard, University
of Heidelberg. Cell lines were cultured in Dulbecco's modified Eagle
medium complemented with 10% fetal calf serum. E64
[trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane], pepstatin, leupeptin, PMSF (phenylmethanesulfonyl fluoride), and all
other chemicals were from Sigma; [
-32P]ATP was
purchased from Hartmann Analytics. Antiserum SAK14 to the N terminus of
NIK, raised in rabbits immunized with the peptide VMEMAYPGAPGSAVGQQKELC, was a kind gift of Jeremy Saklatvala, Kennedy Institute of Rheumatology, London, England. M2 antibodies against the
Flag epitope (M2 agarose beads and Bio-M2) were from Kodak; antibodies
12CA5 against the hemagglutinin (HA) epitope and 9E10 against the c-Myc
epitope were from Boehringer Mannheim. Epidermal growth factor (EGF)
and horseradish peroxidase-coupled secondary antibodies against mouse,
rabbit, and rat immunoglobulin G (IgG) were from Sigma. Protein A-,
protein G-, and glutathione (GSH)-Sepharose were from Pharmacia. Human
recombinant IL-1
was produced as described previously
(24).
Plasmids.
The expression plasmid for glutathione
S-transferase (GST)-Jun (amino acids 1 to 135) was a kind
gift of J. R. Woodgett, The Ontario Cancer Research Institute. GST
fusion proteins were expressed and purified from Escherichia
coli by standard methods. PCS3MT-MKK7 encodes Myc-tagged MKK7
(19). Mutations were introduced to replace amino acids
serine 271, threonine 275, and serine 277 with glutamic acid in
pCS3MT-MKK73E and with alanine in pCS3MT-MKK73A. pCS3MT-MKK7K149M was
mutated to replace the ATP-binding lysine at position 149 in kinase
domain II with methionine. pCDNA3flagNIK and pCDNA3flagNIK(KK429-430AA) encode N-terminally Flag-tagged wild-type and dominant negative NIK,
respectively (33). BamHI/XhoI
fragments of both plasmids were subcloned into the
BglII/XhoI sites of pCS3MT to generate pCS3MT-NIK
and pCS3MT-NIK(KK429-430AA) encoding the N-terminally Myc-tagged
proteins. The cDNAs of human MKK6 (GenBank accession no. U39656) and
JNK2 (GenBank accession no. L31951) were amplified from KB cell RNA by
reverse transcription (RT)-PCR and cloned into the KpnI site
of plasmid peVHA (24), which adds an N-terminal HA epitope
tag. Serine 207 and threonine 211 (according to reference
50) in MKK6 were mutated to glutamic acid to
generate peVHA-MKK62E. In MKK6K82A, the ATP-binding lysine at position 82 was mutated to alanine. Plasmid pFC-MEKK1 encoding amino acids 360 to 672 of MEKK1 was obtained from Stratagene. A 180-nucleotide fragment
of the human IL-8 promoter (nucleotides 1348 to 1527 in GenBank
accession no. M28130) was amplified from genomic DNA by PCR. To
generate the IL-8 promoter-driven luciferase reporter plasmid
pUHC13-3-IL-8pr, the fragment was cloned into the
XhoI/SalI sites of plasmid pUHC13-3
(14), replacing the tet transactivator-controlled and cytomegalovirus promoter sequences. Site-directed mutagenesis of
AP-1 and NF-
B sites was performed as described by others
(64), using the following oligonucleotides (binding sites in
capital letters; point mutations underlined): AP-1,
5'gaagtgtgaTATCTCAggtttgccc3'; and NF-
B,
5'gggccatcagttgcaaatcgTTAACTTTCCtctgacataatg3'.
Transfections and preparation of cell extracts.
Cells
(1 × 105 to 2.5 × 105/well) were
seeded into six-well plates. The next day, transfections were performed
in triplicate by the calcium phosphate method. KB cells were
transfected by using Dosper (Boehringer Mannheim) according to the
manufacturer's instructions. In all transfections, DNA amounts were
kept constant by adding empty expression plasmids. After 24 h, the
medium was changed and cells were incubated further for 24 h.
Cells from one triplicate transfection were placed on ice; the medium
was removed, and cells were washed once in phosphate-buffered saline and scraped in phosphate-buffered saline. For determination of reporter
gene activity, cells were lysed in ice-cold potassium phosphate buffer
(100 mM, pH 7.4), containing 0.2% Triton X-100, 1 µg of pepstatin
per ml, 10 µg of leupeptin per ml, and 1 mM PMSF. Luciferase activity
was determined by using reagents from Promega. For preparation of
whole-cell extracts, cells were lysed in 10 mM Tris (pH 7.05)-30 mM
NaPPi-50 mM NaCl-1% Triton X-100-2 mM
Na3VO4-50 mM NaF-20 mM
-glycerophosphate
with freshly added 0.5 mM PMSF-0.5 µg leupeptin per ml-0.5 µg of
pepstatin per ml-10 mM p-nitrophenyl phosphate-400 nM
okadaic acid (whole-cell lysis buffer). After 10 min on ice, lysates
were cleared by centrifugation at 10,000 × g for 15 min at 4°C. Nuclear and cytosolic extracts were prepared as described
previously (24). Briefly, cells were suspended and pelleted
in buffer A (10 mM HEPES [pH 7.9], 10 mM KCl, 1.5 mM
MgCl2, 0.3 mM Na3VO4, freshly added
200 µM leupeptin, 10 µM E64, 300 µM PMSF, 0.5 µg of pepstatin
per ml, 5 mM dithiothreitol [DTT], 400 nM okadaic acid, 20 mM
-glycerophosphate). The pellet was resuspended in buffer A
containing 0.1% Nonidet P-40. After centrifugation at 10,000, × g for 5 min at 4°C, supernatants were taken as cytosolic
extracts. Pellets were resuspended in buffer B (20 mM HEPES [pH 7.9],
420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 25% glycerol, 0.3 mM Na3VO4, 20 mM
-glycerophosphate, 200 µM leupeptin, 10 µM E64, 300 µM PMSF, 0.5 µg of pepstatin per ml, 5 mM DTT, 400 nM okadaic acid). After 1 h on ice, nuclear extracts were cleared at 10,000 × g for 5 min at 4°C and
supernatants were collected. Protein concentration of cell extracts was
determined by the Bradford method, and samples were stored at
80°C.
Immunoprecipitation and Western blotting.
One milligram of
whole-cell extract protein from cells transfected with plasmids
encoding Flag-tagged or Myc-tagged proteins was diluted in 500 µl of
immunoprecipitation buffer (20 mM Tris [pH 7.3], 154 mM NaCl, 50 mM
NaF, 1 mM Na3VO4, 1% Triton X-100). Samples
were incubated for 4 h with 20 µl of M2-agarose beads or with 2 µg of anti-Myc antibody 9E10 to which 20 µl of protein G-Sepharose
was then added. Beads were spun down, washed three times in 500 µl of
immunoprecipitation buffer, and resuspended in 40 µl of sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample
buffer (2% SDS, 25 mM Tris [pH 6.8], 1%
-mercaptoethanol, 6%
glycerol, 0.02% bromophenol blue). Proteins were eluted from the beads
by boiling for 5 min, separated by SDS-PAGE on a 7.5 or 10% gel and
electrophoretically transferred to polyvinylidene difluoride membranes
(Immobilon; Millipore). After blocking with 5% dried milk in
Tris-buffered saline overnight, membranes were incubated for 4 to
24 h with primary antibodies, washed in Tris-buffered saline, and
incubated for 2 to 4 h with the peroxidase-coupled secondary
antibody. Proteins were detected by using the Amersham enhanced
chemiluminescence system.
SAPK/JNK assay.
The assay was performed as previously
described (24, 49). Briefly, 10 µl of whole-cell extract
containing 30 µg of protein was incubated with 10 µl of GST-Jun (1 µg) and 10 µl of kinase buffer (150 mM Tris, [pH 7.4], 30 mM
MgCl2, 60 µM ATP, 4 µCi of [
-32P]ATP).
After 15 min at room temperature, 10 µl of GSH-beads, equilibrated in
whole-cell lysis buffer containing 1 mM DTT, was added. Samples were
agitated for 30 min at room temperature. Beads were recovered by
centrifugation at 10,000 × g for 5 min and washed twice in 200 µl of whole-cell lysis buffer. Bound GST-Jun was eluted
from the beads by boiling for 5 min in SDS-PAGE sample buffer. After
centrifugation at 10,000 × g for 5 min, supernatants were separated by SDS-PAGE on a 10% gel. Equal recovery of GST-Jun was
confirmed by Coomassie staining.
Electrophoretic mobility shift assay (EMSA).
A
double-stranded oligonucleotide containing (in capitals) the NF-
B
consensus sequence (5'tgacagagGGGACTTTCCagaga3') was end
labeled by using [
-32P]ATP and T4 polynucleotide
kinase and purified by gel filtration on S-200 spin columns
(Pharmacia). Protein-DNA binding reactions were performed with 5 to 20 µg of whole-cell or nuclear extract protein, labeled oligonucleotide,
and 1 µg of poly(dI-dC) in 10 mM Tris (pH 7.4)-10 mM EDTA-0.5%
(wt/vol) dried nonfat milk-0.5 M NaCl-10 mM DTT-50% glycerol in a
total volume of 10 µl. After incubation at room temperature for 30 min, protein-DNA complexes were resolved by PAGE on a 4% gel and
visualized by autoradiography.
RNA stability measurements. HeLa cells constitutively expressing the tet transactivator protein (14) were seeded into 9-cm-diameter petri dishes (5 × 106 cells per dish). The next day, cells were transfected by the calcium phosphate method as described above. After 8 h, cells from each dish were divided into five 25-cm2 flasks for assaying the time course of RNA decay. The next day, transcription from the tet transactivator-controlled promoter was stopped by adding the tetracycline analog doxycycline (3 µg/ml) to the culture medium. At indicated times thereafter, total RNA was isolated by using a Qiagen RNA extraction kit according to the manufacturer's instructions. Then 10 µg of RNA of each sample was separated by denaturing 1% agarose gel electrophoresis in 20 mM morpholine propanesulfonic acid (pH 7.0)-1 mM EDTA-5 mM sodium acetate-6.8% formaldehyde. RNA was blotted onto nitrocellulose Hybond-N membranes (Amersham) by capillary transfer. The membranes were incubated in prehybridization buffer (50% formamide, 20% blocking reagent [Boehringer Mannheim], 5× SSC [1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate], 0.02% SDS, 0.1% N-lauryl sarcosine) for 2 h at 68°C, followed by overnight hybridization in the same buffer containing an IL-8 antisense RNA probe, which was transcribed from the IL-8 cDNA inserted in Bluescript vector and labeled with digoxigenin by using commercial kits (Boehringer Mannheim). Thereafter the membranes were washed twice in 2× SSC-0.1% SDS at room temperature and twice in 0.1× SSC-0.1% SDS at 68°C. Blots were then incubated with an anti-digoxigenin-alkaline phosphatase-coupled antibody and developed by using CSPD {disodium3-[4-methoxyspiro (1,2-dioxetane-3,2'-(5'chloro)tricyclo(3.3.1.1.3,7)decan)-4-yl]phenyl phosphate} as the substrate, and chemiluminescence was visualized on X-ray films (X-Omat; Kodak). Films were scanned with the GelDoc100system and quantified with the Molecular Analyst program (Bio-Rad).
Enzyme-linked immunosorbent assay (ELISA). IL-8 protein concentrations in the cell culture medium, collected between 24 and 48 h after transfection unless stated otherwise, were determined by using the human IL-8 duo set kit (Genzyme) exactly as instructed by the manufacturer.
Statistics. Samples from ELISA and luciferase reporter determinations were analyzed by paired Student t-test. Results are presented as means ± standard errors of the means (SEM).
| |
RESULTS |
|---|
|
|
|---|
The SAPK/JNK-activating kinase MKK7 induces IL-8 alone and in synergy with NIK. We have previously demonstrated that inhibition of SAPK/JNK results in impaired formation of IL-8 in response to IL-1, indicating an essential role of this signaling pathway (24). In the present study, we have further analyzed which pathways activated by IL-1 contribute to expression of IL-8. SAPK/JNK require phosphorylation of tyrosine and threonine within the conserved motif TGY by dual-specificity MAP kinase kinases (39). Recently, a novel MAP kinase kinase, MKK7, also called JNKK2 or SKK4, which specifically activates SAPK/JNK was identified (13, 19, 27, 41, 65). IL-1 activates MKK7 (27, 65) and we have shown that this enzyme is a physiologically relevant activator of SAPK/JNK utilized by IL-1 in vivo (13).
All MAP kinase kinases require phosphorylation at conserved Ser/Thr residues in subdomain XIII of the protein for activation. Substitution of these Ser/Thr residues with charged or uncharged amino acids generates constitutively active or inactive forms of MAP kinase kinases, respectively, as shown for MKK1, MKK3, and MKK6 (34, 50). An active MKK7 mutant was constructed by replacing S271, T275, and S277 with glutamic acid (MKK73E). To obtain an inactive mutant, these amino acids were replaced by alanine (MKK73A). A second inactive mutant was generated by mutating the ATP binding site (MKK7K149M). The activity of these mutants and wild-type MKK7 toward JNK2 was analyzed in cotransfection experiments. As shown in Fig. 1, only the MKK73E mutant showed significant activation of coexpressed HA-JNK2 in intact cells (about fivefold increase in GST-Jun phosphorylation compared to cells transfected with HA-JNK2 only), whereas MKK73A and MKK7K149M were inactive.
|
|
B in the
activation of the IL-8 promoter in response to extracellular stimuli
(1, 5, 10, 16, 18, 21, 30, 35, 43, 45, 46, 57, 64).
Expression of NIK in HEK-293 cells strongly activated NF-
B (Fig.
3A and B). IL-8 secretion in those cells was increased about threefold compared to vector-transfected cells (Fig. 3C). A kinase-inactive form of NIK, NIK(KK429-430AA), which did
not affect NF-
B activity (Fig. 3A) did not induce but rather suppressed IL-8 synthesis compared with the vector control (Fig. 3C).
This is not reflected in decreased NF-
B activity, possibly because
total NF-
B activity in the vector-transfected cells may be
contributed only to a small part by endogenous NIK. The extent of IL-8
induction and NF-
B activation by empty pCDNA3 vector reproducibly
surpassed that of empty pCS3MT. Therefore, for subsequent experiments
NIK and NIK(KK429-430AA) were recloned into pCS3MT.
|
B pathways by MKK73E (Fig. 2) and NIK (Fig. 3), respectively, were lower than those in cultures of cells transfected with an expression vector for a constitutively active form of MEKK1 (Fig. 3C).
The low induction of IL-8 by NIK could not be ascribed to insufficient
activation of NF-
B, since its extent was similar to that induced by
MEKK1 (see Fig. 5C). Considering that MEKK1 can activate SAPK/JNK as
well as NF-
B pathways, we asked whether both pathways might
synergize to induce IL-8. As shown in Fig. 4A, coexpressing NIK and MKK73E induced
supra-additive formation of IL-8 protein. This could not be ascribed to
increased expression levels of NIK and MKK7 (Fig. 4B), since amounts of
both kinases were similar in single and combined transfections (weaker
intensity of the NIK band in the cotransfection in the particular
experiment shown in Fig. 4B was not reproduced in other experiments
[see also Fig. 5 and 7).
|
MKK7 and NIK selectively activate SAPK/JNK and NF-
B,
respectively.
Since both NIK and MKK73E triggered IL-8 formation,
it was important to determine whether they acted via the same or
different downstream effector molecules. Furthermore, since the
combined effect of NIK and MKK73E on IL-8 formation was still far below that of MEKK1 (compare IL-8 concentrations in Fig. 3C and 4A), it was
of interest to determine whether this was based on different intensities of signals induced. Therefore, activation of signaling mechanisms by MKK7 and NIK alone and in combination, as well as by
MEKK1, were assayed. Compared to cells transfected with vector alone,
expression of MKK73E resulted in marked activation of SAPK/JNK2 (Fig.
5A and B). No significant influence on
SAPK/JNK activity was observed by expressing inactive MKK73A or active
or inactive forms of NIK. Cotransfection of NIK did not significantly
influence MKK73E-induced SAPK/JNK activation. Of note, MEKK1 clearly is more active than MKK73E in activating SAPK/JNK, suggesting that a more
efficient trigger of that pathway, in combination with NIK, would give
rise to stronger formation of IL-8. As no other selective activator for
SAPK/JNK is available at present, this cannot be tested directly.
Determination of NF-
B activity in EMSA, performed in parallel for
the same cultures (Fig. 5C), showed that the active form of NIK
strongly induced complex formation with the labeled oligonucleotide,
while NIK(K429-430AA) as well as both forms of MKK7 were inactive in
that respect. Furthermore, the active MKK73E did not affect the extent
of NF-
B activation by NIK. Note that MEKK1-induced NF-
B
activation is not stronger but comparable to NIK-induced activation.
This argues against insufficient NF-
B activation by NIK as an
explanation for its low IL-8 induction. Taken together, these results
confirm selective activation of the SAPK/JNK pathway by MKK7 and of the
NF-
B pathway by NIK, thus arguing against induction of IL-8 by MKK7
through cross-activation of NF-
B.
|
MKK7 and NIK each require NF-
B and AP-1 cis elements
and synergize to activate a minimal IL-8 promoter.
To further
delineate the mechanisms involved in MKK7-induced IL-8 formation, we
studied its effect on the transcriptional activity of a minimal IL-8
promoter, containing the AP-1 and NF-
B binding sequences (43,
64), placed upstream of a luciferase cDNA (Fig.
6A). MKK73E induced a
threefold increase in luciferase activity, comparable to that induced
by active NIK (Fig. 6B). In agreement with other studies, the induction
of a synthetic promoter consisting of a 5-fold repeat of a consensus
NF-
B site by NIK was much more pronounced (about 10-fold [data not
shown]), arguing for distinct requirements for induction of the
minimal IL-8 promoter. The dominant negative mutant NIK(KK429-430AA)
slightly but reproducibly suppressed activity compared to
vector-transfected cells (Fig. 6B and C), consistent with its
suppression of IL-8 formation (Fig. 3C). The inactive MKK73A did not
have a significant effect (Fig. 6B). Coexpression of both NIK and
MKK73E had a synergistic effect (Fig. 6C). Consistent with its
induction of high levels of IL-8 (Fig. 3C), MEKK1 induced much higher
levels of luciferase activity than the active form of MKK7 or NIK (Fig.
6D). Mutation of the AP-1 site or the NF-
B site or both resulted in
a strong decrease in basal activity and in a loss of inducibility by a combination of NIK and MKK73E (Fig. 6D), as well as by each of them
alone (not shown). Thus, unexpectedly, each of the kinases assayed
requires the presence of both sites for efficient stimulation of
transcription. Furthermore, basal activity in this system appears to
involve NF-
B activity and both sites as well. Activation of the
mutated promoters in MEKK1-transfected cells was also strongly reduced
but still clearly discernible. It is not clear at present whether this
is due to quantitative differences in SAPK/JNK activation or triggering
of additional signaling mechanisms by MEKK1.
|
B-dependent IL-8
transcription (Fig. 6B and C) and protein formation (Fig. 3C), its role
in MKK7-induced promoter activation was tested in a more direct way. As
shown in Fig. 7, cotransfection of the
dominant negative form of NIK(KK429-430AA) resulted in marked
inhibition of the MKK73E-induced luciferase activity. On the other
hand, dominant negative MKK73A only marginally interfered with active NIK-induced transcription. These data support a model in which NF-
B-induced activation of IL-8 transcription is enhanced by SAPK/JNK-induced signaling.
|
Low induction of IL-8 by EGF correlates with insufficient SAPK/JNK
activation.
The hypothesis that cooperation of the SAPK/JNK and
NF-
B pathways is required for maximal IL-8 gene expression is
further supported by observations in human KB cells. In these cells,
IL-1 induced a more than 100-fold increase in IL-8 secretion (Fig. 8A), as well as strong activation of
SAPK/JNK (Fig. 8B) and NF-
B (24). Overexpression of
SAPK
antisense RNA resulted in a strong suppression of IL-1-induced
IL-8 secretion (Fig. 8A and reference 24) without
affecting activation of NF-
B (24). In the same cells, EGF
induced only a 10-fold increase in IL-8 secretion (Fig. 8A). EGF did
not activate SAPK/JNK (Fig. 8B). Accordingly, the EGF-induced IL-8
secretion was not decreased in the cell line overexpressing SAPK
antisense RNA (Fig. 8B). This finding suggests that the extent of IL-8
induction by EGF is limited due to its inability to sufficiently
activate SAPK/JNK.
|
MKK6 contributes to IL-8 induction by stabilizing its mRNA. In addition to activation of transcription, posttranscriptional mechanisms contribute to the induction of IL-8 gene expression (6, 21, 23, 58, 59, 61) and may be regulated by these protein kinase pathways. We therefore investigated the role of NIK and MKK7 in IL-8 mRNA degradation. To compare the half-life of IL-8 mRNA in kinase-activated cells to that in control cells (which express only spurious amounts of the mRNA), it was necessary to transfect cells with a plasmid expressing the IL-8 mRNA. Fusion of a 194-nucleotide fragment of the CAT gene to its 5' UTR allowed us to distinguish the ectopically expressed mRNA by size from the endogenous IL-8 mRNA induced by active kinases. To avoid the use of a general transcriptional inhibitor like actinomycin D, the cDNA was placed under the control of a tetracycline-regulated promoter, which allows rapid and selective inhibition of transcription (14).
HeLa cells constitutively expressing the tet transactivator (14) were transiently transfected with the CAT-IL-8 plasmid together with empty vector or with expression vectors for the different active forms of kinases. Following inhibition of transcription by adding the tetracycline analogue doxycycline, the CAT-IL-8 mRNA rapidly decayed in cells cotransfected with empty vector (half-life of <20 min [Fig. 9]). Cotransfection of plasmids encoding active forms of MKK7 or NIK did not affect RNA degradation. In sharp contrast, cotransfection with MEKK1 resulted in pronounced stabilization of the RNA (half-life of >80 min [Fig. 9]). In addition to activation of NF-
B and SAPK/JNK pathways, MEKK1 has
been shown to activate p38 MAP kinase through the MAP kinase kinase
MKK4/SEK1 (15, 22). MKK4/SEK1 also activates SAPK/JNK
(66). For that reason, we tested the involvement of p38 MAP
kinase in IL-8 mRNA degradation by using an active form of the
p38-activating kinase MKK6, MKK62E. MKK6 specifically activates p38 MAP
kinase but not ERK or SAPK/JNK MAP kinases (50). Expression
of MKK62E increased the stability of the CAT-IL-8 mRNA comparable to
that induced by MEKK1 (Fig. 9). Similar results were obtained with
authentic IL-8 mRNA lacking the CAT cDNA insertion, when the amount of
endogenous IL-8 mRNA (which comigrates with it in Northern blots) was
subtracted (data not shown). Thus, the p38 MAP kinase pathway
contributes to induction of IL-8 synthesis by stabilizing its mRNA.
|
|
B pathways on
IL-8 promoter activity and the mRNA-stabilizing effect of the p38 MAP
kinase pathway.
| |
DISCUSSION |
|---|
|
|
|---|
Leukocyte recruitment and migration toward sites of trauma or infection is essential for innate and adaptive immune reactions. It is initiated by a family of extracellular signaling molecules, termed chemokines (2), of which IL-8 was among the first to be cloned. Control of chemokine production is a crucial step in regulating leukocyte infiltration and hence the intensity of an inflammatory process. This is reflected in the fact that IL-8 is low or absent under normal conditions but highly inducible by a wide range of extracellular stimuli, such as the proinflammatory cytokines IL-1 and TNF (5, 21, 45).
While the IL-8 gene contains a well-characterized promoter region,
information on postreceptor events triggered by inflammatory cytokines
to activate transcription of IL-8 is lacking. Furthermore, only limited
information is available on the contribution of posttranscriptional mechanisms to IL-8 formation. In this report, we show that three distinct protein kinase cascades cooperate on different mechanistic levels to induce IL-8 expression. Appropriate forms of the upstream activators NIK, MKK7, and MKK6 were used to selectively activate the
NF-
B, SAPK/JNK, and p38 MAP kinase pathways, respectively.
Transient ectopic expression of the NF-
B inducing kinase NIK was
sufficient to induce secretion of IL-8 (Fig. 3 and 4) and transcription
from a minimal IL-8 promoter (Fig. 6). These results complement
previous data in which deletion or mutation of binding sites for
NF-
B abolished responsiveness of an IL-8 promoter to IL-1, TNF, or
other stimuli. However, the extent to which transfected NIK induces
IL-8 expression is low compared to its strong activation of NF-
B
(Fig. 3). NIK activates NF-
B as strongly as MEKK1 (Fig. 5C), by
activating IKKs to comparable extents (28, 29, 47, 56). Yet
MEKK1 induces a much stronger expression of IL-8 (Fig. 3 and 6). This
observation suggests that additional MEKK1-activated pathways
contribute to IL-8 induction.
SAPK/JNK are part of another MEKK1-activated pathway. NIK did not activate JNK2 in our experiments (Fig. 5), which is in agreement with two recent reports showing that NIK failed to activate coexpressed JNK1 (48, 56). Importantly, a gain-of-function mutant of the upstream activator of the SAPK/JNK pathway, MKK73E, was as effective as NIK in inducing IL-8 secretion (Fig. 4) and transcription (Fig. 6 and 7). This observation is not totally unexpected, since we previously reported that the SAPK/JNK pathway provides an essential signal for IL-1-induced IL-8 formation in KB cells (24).
While AP-1 represents a major nuclear target for SAPK/JNK in general,
previous studies have disagreed as to the importance of the AP-1 site
in the IL-8 promoter. In contrast to the NF-
B site, which is
essential, the AP-1 site was dispensable in some studies (45,
64), contributed only partially to IL-8 transcription (1,
16, 46, 57), or was equally important (18, 30, 35).
From these observations a model has emerged where the AP-1 site is
required in addition to the NF-
B site for maximal transcription from
the IL-8 promoter (1, 16, 18, 25, 30, 35, 36, 43, 44, 46, 57,
64). In support of this model, simultaneous triggering of NF-
B
and SAPK/JNK by NIK and MKK7 resulted in synergistic activation of IL-8
transcription and secretion (Fig. 4 and 6). MEKK1 was still far more
effective in inducing IL-8 transcription and secretion than the
combined NIK and MKK73E. This correlates with a much stronger
activation of SAPK/JNK by MEKK1 than by MKK73E (Fig. 5B). MEKK1
activates SAPK/JNK through stimulation of both MKK7 and MKK4 (17,
27, 32, 56, 65). The combination of MKK4 and MKK7 might result in
stronger activation of the SAPK/JNK pathway and consequently IL-8 gene
expression than was achievable with the active MKK7 mutant alone.
However, it is also possible that MEKK1 activates a third pathway
enhancing IL-8 expression.
The IL-8 promoter provided a model with which to study the relative
contribution of NIK- and MKK7-induced pathways to activation of a
natural promoter containing a single NF-
B site and a single AP-1
site. We found that NIK and MKK7 acted through separate immediate downstream events, since NIK did not activate SAPK/JNK and MKK7 did not
activate NF-
B (Fig. 5). Mutational analysis of the IL-8 promoter
showed that NIK and MKK73E each required functional AP-1 and NF-
B
sites for IL-8 transcriptional activation (Fig. 6). These data suggest
that signals from the NF-
B and the SAPK/JNK pathways converge at the
same sites on the IL-8 promoter. Two observations indicate that the
MKK7 signal may serve to further enhance transcription which is
activated by NF-
B, rather than inducing transcription independently:
First, MKK7-induced transcription is inhibited by coexpression of
dominant negative NIK (Fig. 7). Second, basal IL-8 transcription is
also inhibited by dominant negative NIK, indicating that some NF-
B
activity is involved. Basal NF-
B activity may be necessary to
observe transcriptional activation by MKK7. On the other hand, neither
basal nor NF-
B-activated transcription was sensitive to coexpression
of dominant negative MKK7, arguing against basal activity of that pathway.
These data can be explained by a model in which NIK induces
translocation of the NF-
B dimer to the IL-8 promoter, where it binds
in close proximity to AP-1 proteins. Activated SAPK/JNK molecules bound
to AP-1 may phosphorylate NF-
B subunits or other regulatory
components in addition to phosphorylating AP-1. This could lead to
enhanced IL-8 promoter activity.
In that model, the SAPK/JNK pathway is used by the cell to boost IL-8
transcription initiated by NF-
B. Support for a crucial role of the
SAPK/JNKs in IL-8 (and IL-6) formation comes from experiments in which
IL-1-induced cytokine secretion was strongly reduced by inhibiting
SAPK/JNK, but activation of NF-
B was unimpaired (24). The
fact that EGF, a poor activator of SAPK/JNK, induced only low levels of
IL-8 secretion also supports the notion that SAPK/JNK is required for
the formation of this cytokine. EGF is also a weak activator of NF-
B
(23a).
Several studies have suggested that IL-8 mRNA stabilization may be
induced by IL-1 or TNF, but the signaling pathways involved have not
been identified (6, 21, 58, 59, 61). By using an inducible
expression system which allows rapid transcriptional shutoff, we found
no effect of NIK or MKK7 on IL-8 mRNA degradation. However, an active
mutant of MKK6, a specific activator of p38 but not SAPK/JNK or ERK MAP
kinases (50), stabilized the IL-8 mRNA (Fig. 9). These data
define a novel function for MKK6, namely, regulating IL-8 mRNA
stability. During further analysis of this effect (62a), we
also observed MKK6-induced stabilization of IL-6 mRNA and of
-globin-reporter mRNAs carrying AU-rich sequences of different
cytokine mRNAs in their 3' UTRs. An unrelated transcript (of the CAT
gene) was not affected. This finding suggests that AU-rich elements are
involved in the observed regulation. Recently it was shown that the
SAPK/JNK pathway regulates the stability of the IL-2 (8) and
IL-3 (42) mRNAs. JNKK2 (MKK7) and MEKK1, but not MKK6,
enhanced IL-2 mRNA stability, suggesting that the SAPK/JNK pathway was
involved (8). In discordance with the latter results, MKK7
did not affect IL-8 mRNA decay in our study. We do not know whether
this discrepancy is related to the difference in the transcripts and/or
the cell types studied (T cells versus epithelial cells). In support of
our results, it was recently shown that the p38 MAP kinase inhibitor
SB203580 suppressed IL-1- or lipopolysaccharide-induced stabilization
of cyclo-oxygenase II (9, 52) and IL-6 (40)
mRNAs. In summary, our data suggest that NIK- and MKK7-dependent
pathways cooperatively regulate IL-8 transcription, whereas a third
protein kinase cascade involving p38 MAP kinase regulates IL-8 mRNA
stability. Thus, high expression of IL-8 requires at least three
distinct protein kinase cascades (Fig. 10). Stimuli which are capable
of activating NF-
B, SAPK/JNK, and p38 MAP kinase cascades, such as
TNF, IL-1, or the upstream kinase MEKK1, consequently result in maximal
IL-8 production and secretion.
In conclusion, our results provide a striking example of usage of three signal transduction pathways for regulating the expression level of an endogenous gene.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by grants Kr1143/2-1, SFB 244/B15, and SFB 244/B18 from the Deutsche Forschungsgemeinschaft to H.H. and M.K.
We thank Hermann Bujard for providing plasmids pUHD10-3 and pUHC13-3 and HeLa cells expressing the tet transactivator protein, J. R. Woodgett for his gift of expression plasmid for GST-Jun, and Jeremy Saklatvala for providing antiserum SAK14 against NIK and for helpful discussions. We gratefully acknowledge the skillful technical assistance of Birgit Ritter.
| |
FOOTNOTES |
|---|
*
Corresponding author. Mailing address: Institute of
Molecular Pharmacology, Medical School Hannover, Carl-Neuberg-Stra
e
1, D-30625 Hannover, Germany. Phone: 0049-511-532-2800. Fax:
0049-511-532-4081. E-mail:
Kracht.Michael{at}MH-Hannover.de.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Aihara, M., D. Tsuchimoto, H. Takizawa, A. Azuma, H. Wakebe, Y. Ohmoto, K. Imagawa, M. Kikuchi, N. Mukaida, and K. Matsushima. 1997. Mechanisms involved in Helicobacter pylori-induced interleukin-8 production by a gastric cancer cell line, MKN45. Infect. Immun. 65:3218-3224[Abstract]. |
| 2. | Baggiolini, M. 1998. Chemokines and leukocyte traffic. Nature 392:565-568[Medline]. |
| 3. |
Bergmann, M.,
L. Hart,
M. Lindsay,
P. J. Barnes, and R. Newton.
1998.
I B degradation and nuclear factor- B DNA binding are insufficient for interleukin-1 and tumor necrosis factor- -induced B-dependent transcription.
J. Biol. Chem.
273:6607-6610 |
| 4. |
Bird, T. A.,
K. Schooley,
S. K. Dower,
H. Hagen, and G. D. Virca.
1997.
Activation of nuclear transcription factor NF B by interleukin-1 is accompanied by casein kinase II-mediated phosphorylation of the p65 subunit.
J. Biol. Chem.
272:32606-32612 |
| 5. |
Brasier, A. R.,
M. Jamaluddin,
A. Casola,
W. Duan,
Q. Shen, and R. P. Garofalo.
1998.
A promoter recruitment mechanism for tumor necrosis factor- -induced interleukin-8 transcription in type II pulmonary epithelial cells.
J. Biol. Chem.
273:3551-3561 |
| 6. |
Chaudhary, L. R., and L. V. Avioli.
1996.
Regulation of interleukin-8 gene expression by interleukin-1 , osteotropic hormones, and protein kinase inhibitors in normal human bone marrow stromal cells.
J. Biol. Chem.
271:16591-16596 |
| 7. | Chen, C.-Y. A., and A.-B. Shyu. 1995. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem. Sci. 20:465-470[Medline]. |
| 8. |
Chen, C. Y.,
F. Del Gatto-Konczak,
Z. Wu, and M. Karin.
1998.
Stabilization of interleukin-2 mRNA by the c-Jun NH2-terminal kinase pathway.
Science
280:1945-1949 |
| 9. |
Dean, J. L. E.,
M. Brook,
A. R. Clark, and J. Saklatvala.
1999.
p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes.
J. Biol. Chem.
274:264-269 |
| 10. |
DeForge, L. E.,
A. M. Preston,
E. Takeuchi,
J. Kenney,
L. A. Boxer, and D. G. Remick.
1993.
Regulation of the interleukin-8 gene expression by oxidant stress.
J. Biol. Chem.
268:25568-25576 |
| 11. | Deng, T., and M. Karin. 1994. c-Fos transcriptional activity stimulated by H-ras-activated protein kinase distinct from JNK and ERK. Nature 371:171-175[Medline]. |
| 12. |
DiDonato, J. A.,
M. Hayakawa,
D. M. Rothwarf,
E. Zandi, and M. Karin.
1997.
A cytokine-responsive I B kinase that activates the transcription factor NF B.
Nature
388:548-554[Medline].
|
| 13. | Finch, A., P. Holland, J. Cooper, J. Saklatvala, and M. Kracht. 1997. Selective activation of JNK/SAPK by interleukin-1 in rabbit liver is mediated by MKK7. FEBS Lett. 418:144-148[Medline]. |
| 14. |
Gossen, M., and H. Bujard.
1992.
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Proc. Natl. Acad. Sci. USA
89:5547-5551 |
| 15. |
Guan, Z.,
S. Y. Buckman,
A. P. Pentland,
D. J. Templeton, and A. R. Morrison.
1998.
Induction of cyclooxygenase-2 by the activated MEKK1![]() SEK1/MKK4![]() p38 mitogen-activated protein kinase pathway.
J. Biol. Chem.
273:12901-12908 |
| 16. |
Harant, H.,
R. deMartin,
P. J. Andrew,
E. Foglar,
C. Dittrich, and I. J. D. Lindley.
1996.
Synergistic activation of interleukin-8 gene transcription by all-trans-retinoic acid and tumor necrosis factor- involves the transcription factor NF B.
J. Biol. Chem.
271:26954-26961 |
| 17. |
Hirai, S.,
K. Noda,
T. Moriguchi,
E. Nishida,
A. Yamashita,
T. Deyama,
K. Fukuyama, and S. Ohno.
1998.
Differential activation of two JNK activators, MKK7 and SEK1, by MKN28-derived nonreceptor serine/threonine kinase/mixed lineage kinase 2.
J. Biol. Chem.
273:7406-7412 |
| 18. | Hobbie, S., L. M. Chen, R. J. Davis, and J. E. Gala. 1997. Involvement of mitogen-activated protein kinase pathways in the nuclear responses and cytokine production induced by Salmonella typhimurium in cultured intestinal epithelial cells. J. Immunol. 159:5550-5559[Abstract]. |
| 19. |
Holland, P.,
M. Suzanne,
J. S. Campbell,
S. Noselli, and J. A. Cooper.
1997.
MKK7 is a stress-activated mitogen-activated protein kinase functionally related to hemipterous.
J. Biol. Chem.
272:24994-24998 |
| 20. | Karin, M., Z. Liu, and E. Zandi. 1997. AP-1 function and regulation. Curr. Opin. Cell Biol. 9:240-246[Medline]. |
| 21. |
Kasahara, T.,
N. Mukaida,
K. Yamashita,
H. Yagisawa,
T. Akahoshi, and K. Matsushima.
1991.
IL-1 and TNF- induction of IL-8 and monocyte chemotactic and activating factor (MCAF) mRNA expression in a human astrocytoma cell line.
Immunology
74:60-67[Medline].
|
| 22. |
Khokhatchev, A.,
S. Xu,
J. English,
P. Wu,
E. Schaefer, and M. Cobb.
1997.
Reconstitution of mitogen-activated protein kinase phosphorylation cascades in bacteria.
J. Biol. Chem.
272:11057-11062 |
| 23. |
Kowalski, J., and D. T. Denhardt.
1989.
Regulation of the mRNA for monocyte-derived neutrophil-activating peptide in differentiating HL60 promyelocytes.
Mol. Cell. Biol.
9:1946-1957 |
| 23a. | Kracht, M. Unpublished data. |
| 24. |
Krause, A.,
H. Holtmann,
S. Eickemeier,
R. Winzen,
M. Szamel,
K. Resch,
J. Saklatvala, and M. Kracht.
1998.
Stress-activated protein kinase/Jun-N-terminal kinase is required for interleukin-1-induced IL-6 and IL-8 gene expression in the human epidermal carcinoma cell line KB.
J. Biol. Chem.
273:23681-23689 |
| 25. |
Kunsch, C.,
R. K. Lang,
C. A. Rosen, and M. F. Shannon.
1994.
Synergistic transcriptional activation of the IL-8 gene by NF B p65 (RelA) and NF-IL6.
J. Immunol.
153:153-163[Abstract].
|
| 26. |
Lange-Carter, C. A.,
C. M. Pleiman,
A. M. Gardner,
K. J. Blumer, and G. L. Johnson.
1993.
A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf.
Science
260:315-319 |
| 27. | Lawler, S., A. Cuenda, M. Goedert, and P. Cohen. 1997. SKK4, a novel activator of stress-activated protein kinase-1 (SAPK/JNK). FEBS Lett. 414:153-158[Medline]. |
| 28. |
Lee, F. S.,
J. Hagler,
Z. J. Chen, and T. Maniatis.
1997.
Activation of the I B kinase complex by MEKK1, a kinase of the JNK pathway.
Cell
88:213-222[Medline].
|
| 29. |
Lee, F. S.,
R. T. Peters,
L. C. Dang, and T. Maniatis.
1998.
MEKK1 activates both I B kinase and I B kinase .
Proc. Natl. Acad. Sci. USA
95:9319-9324 |
| 30. | Lee, L.-F., S. J. Haskill, N. Mukaida, K. Matsushima, and J. P.-Y. Ting. 1997. Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter. Mol. Cell. Biol. 17:5097-5105[Abstract]. |
| 31. |
Lin, A.,
A. Minden,
H. Martinetto,
F.-X. Claret,
C. Lange-Carter,
F. Mercurio,
G. L. Johnson, and M. Karin.
1995.
Identification of a dual specificity kinase that activates the jun kinases and p38-mpk2.
Science
268:286-290 |
| 32. |
Lu, X.,
S. Nemoto, and A. Lin.
1997.
Identification of c-Jun NH2-terminal protein kinase (JNK)-activating kinase 2 as an activator of JNK but not p38.
J. Biol. Chem.
272:24751-24754 |
| 33. |
Malinin, N. L.,
M. P. Boldin,
A. V. Kovalenko, and D. Wallach.
1997.
MAP3K-related kinase involved in NF B induction by TNF, CD95 and IL-1.
Nature
385:540-544[Medline].
|
| 34. |
Mansour, S. J.,
W. T. Matten,
A. S. Hermann,
J. M. Candia,
S. Rong,
K. Fukasawa,
G. F. Vande Woude, and N. G. Ahn.
1994.
Transformation of mammalian cells by constitutively active MAP kinase kinase.
Science
265:966-970 |
| 35. |
Mastronarde, J. G.,
M. M. Monick,
N. Mukaida,
K. Matsushima, and G. W. Hunninghake.
1998.
Activator protein-1 is the preferred transcription factor for cooperative interaction with nuclear factor- B in respiratory syncytial virus-induced interleukin-8 gene expression in airway epithelium.
J. Infect. Dis.
177:1275-1281[Medline].
|
| 36. |
Matsukaka, T.,
K. Fujikawa,
Y. Nishio,
N. Mukaida,
K. Matsushima,
T. Kishimoto, and S. Akira.
1993.
Transcription factors NF-IL6 and NF B synergisti |